ORIC Pharmaceuticals, Inc.

NasdaqGS ORIC

ORIC Pharmaceuticals, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024

ORIC Pharmaceuticals, Inc. Net Cash Used Provided By Financing Activities is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

ORIC Pharmaceuticals, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 1.25 M, a -99.28% change year over year.
ORIC Pharmaceuticals, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 173.82 M, a 39.10% change year over year.
ORIC Pharmaceuticals, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 124.96 M.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGS: ORIC

ORIC Pharmaceuticals, Inc.

CEO	Dr. Jacob M. Chacko M.B.A., M.D.
IPO Date	April 24, 2020
Location	United States
Headquarters	240 East Grand Avenue
Employees	112
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Key trends

Past 5 years